On NPR’s All Things Considered, Sydney Lupkin asked DrugPatentWatch if drug patents could be used to identify injector pens which could then be swapped to fix drug shortages.
Referring to the shortage of Ozempic, a patient asked whether the Norditropin pen could be used to deliver it:
Maybe Novo Nordisk, struggling to meet surging demand for Ozempic, diverted plastic pens away from Norditropin to use them for Ozempic.
Listen to the episode, or read the transcript with my answer, at https://www.npr.org/sections/health-shots/2023/05/15/1176220138/families-scramble-to-find-growth-hormone-drug-as-shortage-drags-on
